{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"23"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Progressive Disease (PD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, summarized using frequencies and percentages.","groups":[{"description":"Eribulin mesylate (1.4 mg/m2) administered intravenously (IV) over 2-5 minutes on days 1 and 8 of a 21 day cycle. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Eribulin Mesylate)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants receiving at least 1 dose of study intervention and at least 1 assessment post-baseline.","reportingStatus":"POSTED","timeFrame":"From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}